Trial reportDrug design, development and therapy2025
Effective Dose of Oliceridine for Inhibiting Hemodynamic Elevation Induced by Tracheal Intubation: An Up-and-Down Sequential Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07134660 (Analgesic Efficacy Between Liposomal Bupivacaine and Bupivacaine Hydrochloride in Intercostal Nerve Block for Thoracic Surgery), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analgesic Efficacy Between Liposomal Bupivacaine and Bupivacaine Hydrochloride in Intercostal Nerve Block for Thoracic Surgery: A Multicenter Randomized Controlled Trial
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the effective dose of oliceridine for suppressing hemodynamic responses to tracheal intubation during general anesthesia induction and to evaluate the influence of age on dosing requirements, thereby providing evidence for clinical medication protocols. Methods: A prospective single-center sequential dosing trial was conducted using a modified Dixon's up-and-down method. Patients scheduled for elective surgery under general anesthesia with tracheal intubation were enrolled and divided into a young group (18-65 years) and an elderly group (≥65 years). The initial doses were 45 μg/kg for the young group and 39 μg/kg for the elderly, with 3 μg/kg adjustments based on intubation response until seven crossovers occurred. A positive cardiovascular response was defined as an increase in mean arterial pressure or heart rate exceeding 20% from baseline within 3 minutes after intubation initiation. ED50 and ED95 values were estimated using Probit regression. Secondary outcomes included the incidence of injection-related cough, sedation success rate (MOAA/S score ≤2), peri-intubation hemodynamic changes, and adverse events. Results: Fifty-eight patients were enrolled (28 young, 30 elderly). The ED50 of oliceridine was 46.5 μg/kg (95% CI 42.0-51.19) and ED95 was 55.4 μg/kg (95% CI 43.58-86.56) in the young group. In the elderly group, ED50 was 39.73 μg/kg (95% CI 34.17-44.76) and ED95 was 50.11 μg/kg (95% CI 37.31-77.87). Probit models demonstrated good fit in both groups. No injection-related cough reactions were observed, and the sedation success rate was 100%. Heart rate and blood pressure decreased during induction and normalized after intubation, with no significant intergroup differences. Adverse event incidence was comparable between groups. Conclusion: Under standardized general anesthesia induction, the ED95 of oliceridine for suppressing tracheal intubation-induced hemodynamic elevation shows age-related differences, being approximately 55 μg/kg in younger patients and 50 μg/kg in the elderly. Clinical Trial Registration: ClinicalTrials.gov, NCT07134660.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.